A case series about the favorable effects of sacubitril/valsartan on anthracycline cardiomyopathy
Anthracyclines are the cornerstone of treatment for many solid and hematological cancers such as breast cancer or lymphoma for the past 50 years. Nevertheless, in a non-negligible proportion of patients, they elicit dilated cardiomyopathy as a side effect, which causes in turn cardiac decompensation...
Main Authors: | Renato De Vecchis, Andrea Paccone |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-09-01
|
Series: | SAGE Open Medical Case Reports |
Online Access: | https://doi.org/10.1177/2050313X20952189 |
Similar Items
-
Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report
by: Marcely Gimenes Bonatto, et al.
Published: (2020-06-01) -
Sacubitril/valsartan alleviates myocardial fibrosis in diabetic cardiomyopathy rats
by: Jiao Ai, et al.
Published: (2021-09-01) -
Sacubitril/Valsartan for heart failure
by: Wenqin Dai, MM, et al.
Published: (2022-06-01) -
First experience of using valsartan/sacubitril in women with heart failure and breast cancer receiving anthracycline-based adjuvant chemotherapy
by: S. G. Kanorskiy, et al.
Published: (2019-10-01) -
Sacubitril/valsartan: A practical guide
by: Cândida Fonseca, et al.
Published: (2019-05-01)